Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Mire, Chad E ^a,b   Geisbert, Joan B ^a,b   Agans, Krystle N ^a,b   Satterfield, Benjamin A ^a,b   Versteeg, Krista M ^a,b   Fritz, Elizabeth A ^a,b   Feldmann, Heinz ^c   Hensley, Lisa E ^d   Geisbert, Thomas W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS BASED MARBURG VIRUS VACCINE; VIRUS VACCINE; EBOLA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FILOVIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MACACA FASCICULARIS; MALE; MARBURG VIRUS; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; VESICULAR STOMATITIS VIRUS; ANIMAL; CELLULAR IMMUNITY; HUMORAL IMMUNITY; IMMUNOLOGY; MACACA; MARBURG VIRUS DISEASE; PATHOGENICITY; PHYSIOLOGY; PRIMATE; VESICULAR STOMATITIS; VIREMIA; VIROLOGY;

ANIMALS; EBOLA VACCINES; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MACACA; MALE; MARBURG VIRUS DISEASE; MARBURGVIRUS; PRIMATES; VESICULAR STOMATITIS; VIREMIA;

EID: 84899744869     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0094355     Document Type: Article

References (33)

1. Feldmann H, Sanchez A, Geisbert TW,editor (2013) Filoviridae: Ebola and Marburg Viruses. 6th ed. Philadelphia: Lippincott Williams and Wilkins. 923-956 p.
2. Hartman AL, Towner JS, Nichol ST (2010) Ebola and marburg hemorrhagic fever. Clin Lab Med 30: 161-177.
3. Mbonye A, Wamala J, Winyi K, Tugumizemo V, Aceng J, et al. (2012) Repeated outbreaks of viral hemorrhagic fevers in Uganda. Afr Health Sci 12: 579-583.
4. Geisbert TW, Feldmann H (2011) Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 204 Suppl 3: S1075-1081.
5. Falzarano D, Geisbert TW, Feldmann H (2011) Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines 10: 63-77.
6. Geisbert TW, Bausch DG, Feldmann H (2010) Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 20: 344-357.
7. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, et al. (2006) Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80: 9659-9666. (Pubitemid 44435640)
8. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26: 6894-6900.
9. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83: 7296-7304.
10. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790. (Pubitemid 41021212)
11. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367: 1399-1404.
12. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, et al. (2010) Postexposure treatment of Marburg virus infection. Emerg Infect Dis 16: 1119-1122.
13. Kaslow DC (2007) Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter. Hum Vaccin 3: 1-7.
14. Crum-Cianflone NF, Wilkins K, Lee AW, Grosso A, Landrum ML, et al. (2011) Long-term durability of immune responses after hepatitis A vaccination among HIV-infected adults. J Infect Dis 203: 1815-1823.
15. Bautista-Lopez N, Ward BJ, Mills E, McCormick D, Martel N, et al. (2000) Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18: 1393-1401. (Pubitemid 30017852)
16. Lodmell DL, Parnell MJ, Bailey JR, Ewalt LC, Hanlon CA (2002) Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers. Vaccine 20: 2221-2228. (Pubitemid 34497031)
17. Askling HH, Vene S, Rombo L, Lindquist L (2012) Immunogenicity of delayed TBE-vaccine booster. Vaccine 30: 499-502.
18. Behrman A, Lopez AS, Chaves SS, Watson BM, Schmid DS (2013) Varicella immunity in vaccinated healthcare workers. J Clin Virol 57: 109-114.
19. Herrmann KL, Halstead SB, Wiebenga NH (1982) Rubella antibody persistence after immunization. JAMA 247: 193-196. (Pubitemid 12194190)
20. Weibel RE, Stokes J, Jr., Buynak EB, Leagus MB, Hilleman MR (1968) Jeryl Lynn strain live attenuated mumps virus vaccine. Durability of immunity following administration. JAMA 203: 14-18.
21. Lawson ND, Stillman EA, Whitt MA, Rose JK (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92: 4477-4481.
22. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78: 5458-5465. (Pubitemid 38581495)
23. Smith DH, Johnson BK, Isaacson M, Swanapoel R, Johnson KM, et al. (1982) Marburg-virus disease in Kenya. Lancet 1: 816-820. (Pubitemid 12133655)
24. Marzi A, Engelmann F, Feldmann F, Haberthur K, Shupert WL, et al. (2013) Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A 110: 1893-1898.
25. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4: e1000225.
26. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, et al. (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4: e5547.
27. Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, et al. (2012) Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis 6: e1567.
28. Gunther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, et al. (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204 Suppl 3: S785-790.
29. Sullivan NJ, Martin JE, Graham BS, Nabel GJ (2009) Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 7: 393-400.
30. Schmaljohn AL (2013) Protective antiviral antibodies that lack neutralizing activity: precedents and evolution of concepts. Curr HIV Res 11: 345-353.
31. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 Suppl 2: S430-437. (Pubitemid 351417291)
32. Towner JS, Khristova ML, Sealy TK, Vincent MJ, Erickson BR, et al. (2006) Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J Virol 80: 6497-6516. (Pubitemid 43927452)
33. Geisbert TW, Daddario-DiCaprio KM, Geisbert JB, Young HA, Formenty P, et al. (2007) Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J Infect Dis 196 Suppl 2: S372-381. (Pubitemid 351417284)